Zobrazeno 1 - 3
of 3
pro vyhledávání: '"Chitra Kotwaliwale"'
Autor:
Anne Vielle, Jackie Lang, Yan Dong, Sevinc Ercan, Chitra Kotwaliwale, Andreas Rechtsteiner, Alex Appert, Q Brent Chen, Andrea Dose, Thea Egelhofer, Hiroshi Kimura, Przemyslaw Stempor, Abby Dernburg, Jason D Lieb, Susan Strome, Julie Ahringer
Publikováno v:
PLoS Genetics, Vol 8, Iss 9, p e1002933 (2012)
The Caenorhabditis elegans dosage compensation complex (DCC) equalizes X-chromosome gene dosage between XO males and XX hermaphrodites by two-fold repression of X-linked gene expression in hermaphrodites. The DCC localizes to the X chromosomes in her
Externí odkaz:
https://doaj.org/article/f43f8cf7e6aa42c480ecd8b77d089361
Autor:
Katherine A. Kong, Corey Cutler, Yi-Bin Chen, Aliyah R. Sohani, Joseph H. Antin, Alex F. Herrera, Sarah Nikiforow, Vincent T. Ho, Jerome Ritz, John Koreth, Philippe Armand, Haesook T. Kim, Malek Faham, Robert J. Soiffer, Chitra Kotwaliwale, Edwin P. Alyea, Heather Sun, Victoria Carlton, Scott J. Rodig
Publikováno v:
British Journal of Haematology. 175:841-850
Next-generation sequencing (NGS)-based circulating tumour DNA (ctDNA) detection is a promising monitoring tool for lymphoid malignancies. We evaluated whether the presence of ctDNA was associated with outcome after allogeneic haematopoietic stem cell
Autor:
Chitra Kotwaliwale, Diane C. Arthur, Elizabeth Lamping, Adriana Zingone, Diamond Zuchlinski, Katherine R. Calvo, Karen A. Kurdziel, Raul C. Braylan, Rene Costello, Maryalice Stetler-Stevenson, Roger Kurlander, William D. Figg, Constance M. Yuan, Martin Moorhead, Sham Mailankody, Candis Morrison, Irina Maric, Maria Liza Lindenberg, Dickran Kazandjian, Nishant Tageja, Peter L. Choyke, Marcia Mulquin, Mary L Kwok, Debbie Burton, Neha Korde, Yong Zhang, Ola Landgren, Seth M. Steinberg, Ashley Carpenter, Elisabet E. Manasanch, Malek Faham, George Carter, Manisha Bhutani, Mark Roschewski
Publikováno v:
Blood. 124:2105-2105
*Equally Contributed Introduction: Recent studies show better progression-free (PFS) and overall survival (OS) for newly diagnosed multiple myeloma (NDMM) pts achieving MRD negativity by multicolor flow cytometry (MFC) or next-generation sequencing (